Tuesday, August 29, 2017 4:36:56 AM
"The Company has an FDA approved protocol for a human abuse potential study for the intranasal route of abuse, which it plans on commencing in the coming weeks."
it looks like they could likely already be doing the HAP studies for intranasal. For sure (given their modus operandi) they are not going to tell us.
On the prospectus:
they are witing for the definitive document to be approved by the SEC; in fact the "Preliminary" date 26th of May doc was withdrawn.
Now, why withdrawing it without a contextual replacement with the newly approved SEC doc I honestly don't know; it can really be anything, but it is not strictly PER SE linked to a new offering.
reference here
http://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00029068
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM